Heart failure & cardiomyopathies
Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of Heart Failure with Reduced Ejection Fraction (HFrEF) in the VICTORIA Trial
Authors' conclusion
Geographic variation in the phenotype of patients with HFrEF, standard of care, and clinical outcomes was observed, while there was no intra-regional heterogeneity in vericiguat's treatment effect. However, when considering contextual/systemic measures via country-level HDI, further insights into treatment effect were revealed.
Study context
- Population
- Patients with HFrEF from 42 countries, analysed by five prespecified geographic regions
- Participants
- 5,050 patients42 countries
- Comparison
- Vericiguat vs placebo, by geographic region and country-level human development index (HDI)
- Primary endpoint
- Primary composite endpoint (time to first HF hospitalization or CV death) and its components, by geographic region
Methodological detailsprespecified geographic regions
- Prespecified geographic regions
Primary result
As reported in the abstract
- Benefit on HF hospitalization retained overall but attenuated as HDI rose
- Pinteraction = 0.009
- Benefit on primary composite retained overall but attenuated as HDI rose
- Pinteraction = 0.088
- No apparent treatment effect modification by HDI on CV death
- Pinteraction = 0.623
Further findings
- Notable inter-region differences in participant characteristics, standard of care at randomization and clinical outcomes
Original publication
Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial. ESC Heart Fail. Published 22 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →